Drug Trial Radar · NCT06441006
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 3, 2025
Primary completion
Aug 2031
Study completion Aug 2031
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Johns Hopkins University
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PRISM-TB is an international, seamless, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, multi-arm multi-stage (MAMS), noninferiority Phase 2/3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB). In Stage 1, participants will be randomized among one of three treatment arms (one control and two experimental). Following the interim analysis (at the end of Stage 1) based on DOOR outcome comparisons and the entirety of the data, one of the four possible experimental strategies will be identified and continue into Stage 2. In Stage 2, participants will be randomized among one of two treatment arms (one control and one experimental). The trial objective is to identify, among participants with fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17 weeks for participants stratified to receive shorter treatment and 17 or 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, and to evaluate whether this BPaLM strategy has noninferior efficacy to the control strategy at Week 73.
Conditions
- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, MDR
Interventions
BedaquilineDrug
Frequency: daily Route of administration: oral
LinezolidDrug
Frequency: daily Route of administration: oral
PretomanidDrug
Frequency: daily Route of administration: oral
MoxifloxacinDrug
Frequency: daily Route of administration: oral
Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelinesDrug
The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 24 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest international guidelines and the local SOC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy Outcome: Desirability of Outcome Ranking (DOOR)Time frame: 73 weeks
Locations
6 sites in 5 countries. Site status is shown where the registry gives one.
National Center for Communicable Diseases
Ulaanbaatar, Mongolia · Recruiting
Institute of Chest Diseases
Kotri, Pakistan · Not yet recruiting
Hospital Nacional Sergio E. Bernales
Lima, Peru · Recruiting
Policlínico SES
Lima, Peru · Recruiting
Mulago National Referral Hospital
Kampala, Uganda · Recruiting
Hanoi Lung Hospital
Hanoi, Vietnam · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.